Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EMBER-3 in ER-positive, HER2-negative advanced or metastatic breast cancer
jRCT2051210102Phase 3Active, not recruiting
- Sponsor
- Eli Lilly and Company
- Start
- Dec 2021
- Modality
- Small Molecules
01
Overview
Phase 3, randomised, open-label trial of imlunestrant, abemaciclib, exemestane and fulvestrant in breast cancer (3 arms), sponsored by Eli Lilly and Company. Primary endpoints: Progression-free survival in the intent-to-treat population and Progression-free survival in the ESR1-mutation detected population. Started Dec 2021; status: active, not recruiting.
02
Drugs
imlunestrantabemaciclibexemestanefulvestrant
03
Conditions
breast cancer
Beyond the preview
Go deeper on jRCT2051210102.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2051210102.